Clarissa Sowemimo-Coker

Sep 25, 2023 | investing.thisismoney.co.uk | Clarissa Sowemimo-Coker |Emily Staples |Jo Turner |Simon Nayyar

RNS Number : 4227N Oxford Cannabinoid Tech.Holdings 25 September 2023 Oxford Cannabinoid Technologies Holdings plc ("OCTP" or the "Company") Final Dose Administered in Phase I Clinical Trial for Lead Drug Candidate OCT461201 Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, is pleased to announce that the final dose of its lead pharmaceutical drug compound, OCT461201, has been successfully administered, as part...

Jul 19, 2023 | inkl.com | Clarissa Sowemimo-Coker

It comes after a breakthrough by the business identified “a potential ‘first in class’ immunotherapy agent for the treatment of solid tumours”. Immunotherapy uses patients’ immune systems to fight cancer and is currently administered via a drip, as tablets, or as a topical medication on the skin.